Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Down 67.5% in May

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) saw a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 40 shares, a decrease of 67.5% from the May 14th total of 123 shares. Based on an average trading volume of 53 shares, the short-interest ratio is presently 0.8 days. Approximately 0.0% of the shares of the company are short sold.

Orion OYJ Stock Performance

ORINY stock traded down $2.04 during mid-day trading on Friday, reaching $39.00. 150 shares of the stock traded hands, compared to its average volume of 15. The company has a quick ratio of 1.13, a current ratio of 1.77 and a debt-to-equity ratio of 0.10. Orion OYJ has a 52 week low of $25.95 and a 52 week high of $42.75. The business has a 50-day moving average of $38.01 and a two-hundred day moving average of $38.00. The firm has a market capitalization of $11.01 billion, a PE ratio of 17.89 and a beta of 0.08.

Orion OYJ (OTCMKTS:ORINY) last released its quarterly earnings results on Thursday, April 23rd. The company reported $0.37 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 27.14% and a return on equity of 49.17%. The company had revenue of $488.80 million during the quarter.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.